Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[knuts4oe]

Just e-mailed the following message to 22 of the 23 members of the Senate Committee on Health, Education, Labor and Pensions.

Hoping to stir some interest.

"The purpose of this contact is to alert the Senator to a little known possible medical breakthrough which could dramatically lower the demand for medical intervention, and thereby lower the overall cost of the national medical expense burden.

I urge you not to dismiss this as a crank letter, much as I did when I first heard of the breakthrough five years ago. The premise of a “breakthrough” is supported by three peer reviewed and published pre-clinical studies in models of multiple sclerosis, Alzheimer’s disease and autoimmune thyroiditis. Each concluded that study results called for further study.

The alkaloid used in these studies was anatabine citrate. On 23 Mar 2011 an International Patent Filing was made https://www.google.com/patents/WO2011119722A2?cl=en entitled “Use of Anatabine to Treat Inflammation and Methods of Synthisizing Anatabine”. The patent application goes on to explain how anatabine accesses every cell in the body, and safely modulates aberrant inflammation, which in turn can treat or prevent well over 200 inflammatory conditions or diseases.

Much of what is known and proven about this ability of anatabine citrate was discovered
by the team of doctors and clinicians at The Roskamp Institute in Sarasota FL under the leadership of Drs Michael Mullan and Fiona Crawford. It was they that produced the three peer reviewed and published pre-clinical studies. Dr. Mullan is also the Exploitation and Scientific Director of the NILVAD Project, a 500 patient, multi-year phase 3 study of the ability of Nilvadipine to treat mild to moderate Alzheimer’s, which is currently concluding in Europe. Dr. Crawford has been working closely with the Veterans Association for many years in studies of Gulf War Illness (GWI), Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI) and Mild Repetitive Brain Injury (MRBI), and has recently received funding from a congressional program to test veterans with GWI and MRBI using anatabine, and measuring its ability to reduce their symptoms.

The medical and pharmaceutical industries have refrained from any mention of the patent claims or study results, perhaps because an inexpensive, safe and effective anti-inflammatory would reek havoc on the current system, significantly reducing demand for medical treatment and pharmacology.

It is incumbent on members of The Senate Committee on Health, Education, Labor and Pensions to interview both Dr. Mullen and Dr. Crawford in order to determine the potential for lowering medical costs through the use of anatabine as an inexpensive, safe and effective anti-inflammatory!"